Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility

著录项

• 来源
  《ACS medicinal chemistry letters》 |2021年第2期|共7页
• 作者

  Andrew M. Thompson; Patrick D. O’Connor; Vanessa Yardley; Louis Maes; Delphine Launay; Stephanie Braillard; Eric Chatelain; Baojie Wan; Scott G. Franzblau; Zhenkun Ma; Christopher B. Cooper; William A. Denny;

  展开▼
• 作者单位

  Auckland Cancer Society Research Centre School of Medical Sciences The University of Auckland;

  Auckland Cancer Society Research Centre School of Medical Sciences The University of Auckland;

  Faculty of Infectious &

  Tropical Diseases London School of Hygiene &

  Tropical Medicine;

  Laboratory for Microbiology Parasitology and Hygiene Faculty of Pharmaceutical Biomedical and Veterinary Sciences University of Antwerp Universiteitsplein;

  Drugs for Neglected Diseases Initiative;

  Drugs for Neglected Diseases Initiative;

  Drugs for Neglected Diseases Initiative;

  Institute for Tuberculosis Research College of Pharmacy University of Illinois at Chicago;

  Institute for Tuberculosis Research College of Pharmacy University of Illinois at Chicago;

  Global Alliance for TB Drug Development;

  Global Alliance for TB Drug Development;

  Auckland Cancer Society Research Centre School of Medical Sciences The University of Auckland;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 药学;化学;
• 关键词

  pretomanid; leishmaniasis; tuberculosis; Chagas disease; pharmacokinetics; lt; igt; in vivolt; /igt; efficacy;

  机译：伪造者;Leishmaniaisis;结核病;Chagas病;药代动力学;＆lt;I＆gt;在体内＆lt;/ i＆gt;功效;